StockData
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. (SLS) stock

SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$13.66−1.20 (-8.08%)

Close on Nov 20, 2026Market cap $2.76BP/E –Yield –

SELLAS Life Sciences gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

SELLAS Life Sciences's gross profit for the twelve months ending Dec 31, 2023 was $0, down 100.0% year over year. For fiscal 2023 it was $0, down 100.0% from the year before. The highest annual figure on record is $7.92M in fiscal 2014.

Annual gross profit

PeriodPeriod endValueChange
FY2023Dec 31, 2023$0-100.0%
FY2022Dec 31, 2022$900.00K-87.8%
FY2021Dec 31, 2021$7.40M+289.5%
FY2020Dec 31, 2020$1.90M-76.0%
FY2014Dec 31, 2014$7.92M+302.4%
FY2013Dec 31, 2013$1.97M–
FY2012Dec 31, 2012$0–
FY2011Dec 31, 2011$0–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$0–
Q2 FY2023Jun 30, 2023$0–
Q1 FY2023Mar 31, 2023$0-100.0%
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$0–
Q2 FY2022Jun 30, 2022$0-100.0%
Q1 FY2022Mar 31, 2022$900.00K-83.9%
Q4 FY2021Dec 31, 2021$0-100.0%
Q3 FY2021Sep 30, 2021$0–
Q2 FY2021Jun 30, 2021$1.80M–
Q1 FY2021Mar 31, 2021$5.60M–
Q4 FY2020Dec 31, 2020$1.90M–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$0–
Q1 FY2020Mar 31, 2020$0–

More SELLAS Life Sciences figures

See a number that looks wrong?